.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Respiratory syncytial virus (RSV) causes significant lower respiratory tract disease across all age groups. Specifically, older adults face a substantial burden of severe disease and hospitalization. Researchers recently evaluated the IVX-121 RSV vaccine, an investigational virus-like particle (VLP) subunit vaccine, in a first-in-human Phase 1/1b randomized trial. This study assessed the safety and immunogenicity of various dose levels in healthy young and older adults.
The IVX-121 RSV vaccine utilizes advanced VLP technology to display a stabilized prefusion F antigen. This approach mimics the structure of a real virus without containing genetic material. Consequently, the vaccine can trigger a potent immune response while maintaining a high safety profile. During the trial, 90 young adults and 130 older adults received a single intramuscular injection. Participants were randomized to receive low, medium, or high doses, with or without an aluminum hydroxide adjuvant. Furthermore, the trial included a placebo group for rigorous comparison.
The trial results showed that adverse reactions were generally mild. Importantly, there were no serious adverse events related to the vaccine. All tested dose levels successfully boosted preexisting RSV neutralizing antibody (nAb) responses. However, the researchers noted no clear dose-response relationship, and the adjuvant did not significantly improve immunogenicity. For both age groups, the vaccine induced nAbs against both RSV A and B strains. These antibody levels remained significantly above baseline for at least six months. A second dose in older adults provided a modest boost for RSV A, though not for RSV B.
VLP technology involves creating virus-like particles that look like a virus to the immune system but lack viral DNA or RNA. This allows the vaccine to be non-infectious while eliciting a robust antibody response.
Yes, the trial demonstrated that IVX-121 induces neutralizing antibodies against both RSV A and RSV B subtypes in young and older adult populations.
The study found that the adjuvant aluminum hydroxide did not appear to improve the immunogenicity of the vaccine, as unadjuvanted doses were equally effective in boosting antibody levels.
Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or to replace the professional judgment of a healthcare provider. Refer to the latest local and national guidelines for clinical practice.
References
De Coster I et al. A first-in-human Phase 1/1b randomized trial evaluating the safety and immunogenicity of a respiratory syncytial virus (RSV) virus-like particle subunit vaccine (IVX-121) in healthy young and older adults. Hum Vaccin Immunother. 2026 Dec undefined. doi: 10.1080/21645515.2026.2633021. PMID: 41776715.
Icosavax. Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint. FirstWord Pharma. 2022 Dec 13.
Bandla SS et al. Epidemiology of Respiratory Syncytial Virus in Hospitalised Adult Patients with Respiratory Tract Infections. J Clin Diagn Res. 2025;19(4):DC01-DC05.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A Phase 1/1b trial demonstrates that the IVX-121 RSV vaccine is safe and induces durable neutralizing antibody responses in both young and older adults....
6 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
